PDF下载 ( 171 KB)
-
摘要: 目的观察干扰素联合拉米夫定治疗慢性乙型肝炎患者的疗效。方法90例慢性乙型肝炎患者随机分为两组:42例干扰素α-2b联合拉米夫定治疗组,48例单用拉米夫定对照组:观察比较两组患者治疗后HBVDNA水平,乙型肝炎病毒血清标志物及肝功能变化。结果治疗结束时,联合治疗组患者血清中HBVDNA阴性率和肝功能复常率明显高于单用拉米夫定治疗组,联合治疗组完全应答率40.5%,优于单用拉米夫定治疗组22.9%（P<0.01）;随访24周联合治疗组的上述指标仍高于拉米夫定对照组（P<0.05）。结论干扰素α-2b联合拉米夫定治疗慢性乙型肝炎,可提高HBeAg/抗HBe血清转换率及综合应答率,并可防止或减少YMDD变异的发生。Abstract: Objective To inderify the efficacy of combination treatment of Lamivudine and INF-α 2b in patients with chronic hepatitis B.Methods Ninety patients with CHB were divided into two groups casually.The treating group (n=42) was treated with INF-α 2b combined with Lamivudine.While the control group (n=48) was treated with Lamivudine only.HBVDNA, liver function indexes and HBeAg/HBeAb conversion ratio in the plasma of those patients were observed.Results The negative rate of serum HBVDNA and liver function indexes in treating group were obvious better than those in control group at the end of 48 weeks' treatment.The complete response rate was 40.5% in treating group, which was higher than that in control group (22.9%) (P<0.01) .After 24 weeks follow up, those were still higher in the treating group than in control group.Conclusion Combination of Lamivudine and INF-α 2b in the treatment of patients with CHB can get a better effect, which might improve complete response and decrease YMDD mutation.
-
Key words:
- chronic hepatitis B /
- Interferon-α 2b /
- Lamivudine /
- drug combination.
-
[1]Schalm SW, Heathcote J, Cianciara J, et al.Lamivudine and al-pha interferon combination tretment of patients with chronc hepatitisB infection:a randomized trial[J].Gut, 2000, 46∶562-568. [2]赵建军, 李岱.单用拉米夫定与联合干扰素α-2b治疗慢性乙型肝炎对照观察[J].传染病信息, 2005, 18 (3) ∶136-137. [3]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2000, 6∶324-329. [4]顾长海.慢性乙型肝炎干扰素疗法的适应症选择[J].中华肝脏病杂志, 2002, 10 (2) ∶139-142. [5]杨京, 张莉落, 赵雪珂.单用和联合应用拉米夫定和干扰素α-1b对乙型肝炎血清标志物的影响[J].中华肝脏病杂志, 2003, 11∶109-110. [6]Tassopoulos NC, Volpes R, Pastore G, et al.Efficacy of lamivu-dine in patients with HBeAg-negative/HBVDNA-positive chronichepatitis B[J].Hepatology, 1999, 29∶889-894. [7]Villeneu JP, Condreay LD, Willems B, et al.Lamivudine treat-ment for decompensated cirrhosis resulting from chronic hepatitisB[J].Hepatology, 2000, 31∶207-210. [8]Bordens R, lrrossberg SE, Trotta PP, et al.Moleculer and bidog-ic characterization of recombinant interferon-α2b[J].Sem-inaroncot, 1997, 24∶41-45. [9]Lok AS, Lai Cl, Leung N, et al.Long-term safety of lamivudi-ne treatment in patients of with chronic hepatitis B[J].Gastro-genterology, 2003, 125 (6) ∶1714-1722. [10]郑瑞英, 万谟彬, 李成忠, 等.拉米夫定耐药者乙型肝炎病毒的基因突变[J].中华传染病杂志, 2007, 25 (7) ∶412-414. -
本文二维码
计量
- 文章访问数: 2156
- HTML全文浏览量: 15
- PDF下载量: 769
- 被引次数: 0
下载:
